biote Corp. Reports Revenue Decline, Material Weakness in Controls, and Product Recall in 2025 Annual Report

summarizeSummary

biote Corp. reported a 2.5% revenue decline for 2025 and disclosed a material weakness in internal controls over financial reporting, which led to prior financial restatements and remains unremediated. The company also announced a voluntary recall of hormone pellets due to potential metal particulate matter.

check_boxKey Events

• Revenue Decline Reported

  Total revenue for 2025 decreased by 2.5% to $192.2 million, primarily due to a $13.3 million decline in procedure revenue.

• Material Weakness in Internal Controls

  Management reported that internal control over financial reporting was not effective as of December 31, 2025, following prior restatements for Q2 and Q3 2022, with remediation efforts still ongoing.

• Product Recall Initiated

  A voluntary recall of hormone pellets was initiated on January 26, 2026, due to potential metal particulate matter, resulting in a $1.3 million inventory impairment charge in Q4 2025.

• Adjusted EBITDA Decreased

  Adjusted EBITDA for 2025 fell to $53.5 million from $58.2 million in 2024.

auto_awesomeAnalysis

This annual report reveals significant operational and financial challenges for biote Corp., with a decline in overall revenue driven by a substantial drop in core procedure revenue. The disclosure of an unremediated material weakness in internal controls, which previously led to financial restatements, raises serious concerns about the reliability of financial reporting and corporate governance. Further compounding these issues is a voluntary recall of hormone pellets due to quality control problems, directly impacting product integrity and potentially damaging brand reputation. While net income saw a large increase, this was primarily due to a favorable revaluation of earnout liabilities rather than improved operating performance. The company also made a substantial $18.5 million cash payment in January 2026 to settle litigation with a former owner, impacting its liquidity. The company's stock trading near its 52-week low underscores investor apprehension regarding these developments. Investors should monitor the progress of internal control remediation and the impact of the product recall on future sales and regulatory standing.